
|Articles|August 1, 2011
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-08-01-2011
- Volume 23
- Issue 8
Improving API Synthesis
Author(s)Patricia Van Arnum
O-arylation and O-alkylation, a one-pot protein synthesis, a combined approach in continued and chemocatalysis, and green-chemistry applications are the target of some recent advances in API synthesis.
Advertisement
By Patricia Van Arnum
O-arylation and O-alkylation, a one-pot protein synthesis, a combined approach in continued and chemocatalysis, and green-chemistry applications are the target of some recent advances in API synthesis.
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
over 15 years ago
Understanding Fluidized-Bed Granulationover 15 years ago
Controlled Release from Porous Platformsover 15 years ago
Controlled Crystallization During Freeze-Dryingover 15 years ago
Movin' On Outover 15 years ago
The Many Varieties Of 'Emerging'over 15 years ago
Newsover 15 years ago
Managing Information Overloadover 15 years ago
The Importance Of Filter Testingover 15 years ago
Making A Mark In Emerging Marketsover 15 years ago
Croatia, Pharma and CorruptionAdvertisement
Related to this article

The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.

Proposal for the Public Procurement Act, adoption of a new pharmaceutical legislation, and revision of pharmacovigilance practices should improve patient access to safe and innovative medicines in Europe.

This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.

Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.

Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.

Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.

The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Manufacturing Intelligence: AI Poisoning Demands Pharma Data Stewards
3
New Proposals and Legislation Strengthen Europe’s Position in the Pharmaceutical Arena
4
Investing in Protecting Pharma Products
5


